Change in Medivir's Board of Directors
/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) and (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...
Stay updated with breaking news from Uli Hacksell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) and (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...
/PRNewswire/ -- Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023. The annual general meeting was held by physical presence of...
/PRNewswire/ -- "Thanks to the strong interest from clinicians and patients, we were able to swiftly dose the first patients in the phase 2a part of the...
The biotech company SynAct Pharma has important clinical data coming in 2023 and recently expanded its portfolio with the acquisition of TXP Pharma. SynAct is now making a switch in management to... | April 3, 2023
/PRNewswire/ -- The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the...